{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:24:22Z","timestamp":1790745862391,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.autrev.2017.12.010","type":"journal-article","created":{"date-parts":[[2018,4,7]],"date-time":"2018-04-07T14:09:47Z","timestamp":1523110187000},"page":"582-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review"],"prefix":"10.1016","volume":"17","author":[{"given":"Mathilde","family":"Thiebaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mah\u00e9vas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syrine","family":"Bellakhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.12.010_bb0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.rdc.2015.04.002","article-title":"The pathogenesis of systemic sclerosis","volume":"41","author":"Stern","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2017.12.010_bb0010","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2017.12.010_bb0015","first-page":"iii40","article-title":"Pulmonary complications: one of the most challenging complications of systemic sclerosis","volume":"48","author":"Wells","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.12.010_bb0020","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.12.010_bb0025","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMc061920","article-title":"Cyclophosphamide in scleroderma lung disease","volume":"355","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.12.010_bb0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2017.12.010_bb0035","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.12.010_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.12.010_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.12.010_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2017.12.010_bb0055","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.12.010_bb0060","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.rbr.2016.04.001","article-title":"Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center","volume":"56","author":"Vilela","year":"2016","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"10.1016\/j.autrev.2017.12.010_bb0065","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.12.010_bb0070","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/03009742.2015.1069888","article-title":"Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy?","volume":"44","author":"Moazedi-Fuerst","year":"2015","journal-title":"Scand J Rheumatol"},{"issue":"Suppl. 100","key":"10.1016\/j.autrev.2017.12.010_bb0075","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.12.010_bb0080","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","author":"Daoussis","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.12.010_bb0085","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.12.010_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3879","article-title":"B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin","volume":"14","author":"Daoussis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.12.010_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.120778","article-title":"Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement","volume":"40","author":"Smith","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.12.010_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/03009742.2013.869617","article-title":"Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen","volume":"43","author":"Moazedi-Fuerst","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2017.12.010_bb0105","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.12.010_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","article-title":"Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis","volume":"73","author":"Melsens","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.autrev.2017.12.010_bb0115","first-page":"S181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.12.010_bb0120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3899\/jrheum.151018","article-title":"Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study","volume":"43","author":"Smith","year":"2016","journal-title":"J Rheumatol"},{"issue":"Suppl 100","key":"10.1016\/j.autrev.2017.12.010_bb0125","first-page":"148","article-title":"Assessment of sensitivity to change of the European Scleroderma Study Group activity index","volume":"34","author":"Melsens","year":"2016","journal-title":"Clin Exp Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T12:51:00Z","timestamp":1534942260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218300831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1568997218300831"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}